niacinamide has been researched along with veliparib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, Z; Dong, G; He, G; Wang, X; Xu, Y; Zhu, Q | 1 |
| Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H | 1 |
| Baks-Te Bulte, L; Brundel, BJJM; de Groot, NMS; de Vries, AAF; Henning, RH; Hoogstra-Berends, F; Hu, X; Lanters, EAH; Li, J; Liu, J; Malik, NU; Pijnappels, DA; Tolouee, M; van Marion, DMS; van Roon, AM; Wiersma, M; Zhang, D | 1 |
1 trial(s) available for niacinamide and veliparib
| Article | Year |
|---|---|
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure | 2015 |
2 other study(ies) available for niacinamide and veliparib
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Imidazoles; Mice; Molecular Structure; Neoplasms, Experimental; Niacinamide; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2013 |
DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD
Topics: Animals; Atrial Fibrillation; Benzimidazoles; Cells, Cultured; DNA Damage; Drosophila melanogaster; Enzyme Activation; Heart Atria; Humans; Larva; Mice; Models, Cardiovascular; Myocardial Contraction; Myocytes, Cardiac; NAD; Niacinamide; Oxidative Stress; Pacemaker, Artificial; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Pupa; Rats; Rats, Wistar | 2019 |